GlobeNewswire·Apr 23, 2026, 4:05 PM ET

Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering

Outlook Therapeutics, Inc. closed a registered direct offering priced at-the-market for 16,129,033 shares of common stock at $0.31 per share.
The company concurrently issued unregistered warrants to purchase up to 16,129,033 shares at an exercise price of $0.31 per share.
Gross proceeds from the offering totaled approximately $5.0 million before fees and expenses, with potential additional proceeds of $5.0 million if warrants are fully exercised.
H.C. Wainwright & Co. served as the exclusive placement agent for the transaction.
The shares were sold pursuant to an effective Form S-3 shelf registration statement originally filed on March 28, 2024.
The unregistered warrants will become exercisable on the later of stockholder approval for the issuance or the effective date of an amendment to increase authorized shares.
Outlook Therapeutics amended 2,142,854 outstanding warrants previously held by an investor to reduce their exercise price from $2.26 to $0.31 per share.
Net proceeds will primarily be used for working capital and general corporate purposes.
The company is developing ONS-5010/LYTENAVA™ (bevacizumab gamma) to enhance the standard of care for bevacizumab in retina diseases, with commercial launch already underway in Germany, Austria, & the UK.